Kling Bio validates its proprietary B-cell technology for rapid response against emerging viral variants: Amsterdam Wednesday, September 10, 2025, 17:00 Hrs [IST] Kling Bio, the f ...
Germinal center B-cell–like diffuse large B-cell lymphomas (GCB-DLBCLs) show dependence on DOT1L and EZH2, with combined targeting offering potential as an alternative differentiation-based therapy.
Scientists have uncovered how a key type of immune cell adapts its behavior depending on the type of infection, paving the ...
Skoltech researchers and their colleagues from the Pasteur Institute and the University of Lorraine, France, have uncovered ...
New findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment outcomes for pediatric patients with B-cell acute lymphoblastic leukemia (B ...
First-ever clinical data supporting safety and efficacy of in vivo CAR-T Therapy in refractory systemic lupus erythematosus (SLE) patients.Data shows low dose of HN2301 reprogrammed up to 60% of CD8+ ...
waveLINE-010: Zilovertamab vedotin plus R-CHP versus R-CHOP in untreated diffuse large B-cell lymphoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
For the treatment, Lou, a 10-year-old Beagle, and Sadie, an 8-year-old Collie/Pyrenees mix received infusion with CAR-T cells isolated with Akadem’s kit. During the 3-week study, the dogs’ tumors ...
13d
Second cell, tissue and gene therapy product for aggressive blood cancer now subsidised in Singapore
The drug, Yescarta, is reportedly sold in Singapore for about S$480,700. Read more at straitstimes.com. Read more at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback